Sachin Atre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sachin Atre has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
Jayshri Jagtap
Affiliation Dr. D.Y. Patil Medical College, Hospital and Research Centre Dr. D.Y. Patil Vidyapeeth, Pune, India
4 shared publicationsSunil Ambike
Affiliation Dr. D.Y. Patil Medical College, Hospital and Research Centre Dr. D.Y. Patil Vidyapeeth, Pune, India
4 shared publicationsTrupti Sawant
Affiliation Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune, India
4 shared publications- Vidya Mave
Johns Hopkins University
4 shared publications - Amita Gupta
Division of Infectious Diseases, School of Medicine, Johns Hopkins University , Baltimore, Maryland
3 shared publications - Anirvan Chatterjee
HaystackAnalytics Pvt. Ltd., IIT Bombay, Mumbai, India
3 shared publications
Latest Publications
- Open Access
- 17 September 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (9) , e0004617
Awareness of management of pulmonary multidrug-resistant tuberculosis (MDR-TB) among private practitioners in suburban areas of Pune city, India: Input for developing an educational tool
Private practitioners (PPs) play a major role in caring for people with tuberculosis (TB) in India. At the same time, PPs have limited access to continuing medical education and oversight especially with regards to recent changes in the management of multi-drug resistant (MDR- TB). As a part of a larger study aimed at developing an educational tool for improving multidrug-resistant TB management, we conducted a baseline knowledge assessment of MDR-TB among PPs in suburban areas of Pune City, India. This study with a cross-sectional design was conducted during July 2022 to May 2023 among 100 PPs, who either refer and/treat TB and MDR-TB cases in Pimpri-Chinchwad Municipal Corporation (PCMC) areas of Pune in Maharashtra State. The inquiry was made using an interview schedule focused on suspicion of pulmonary TB and MDR-TB, their diagnosis and treatment. The majority of PPs were allopathic practitioners (85%) practicing in private clinics (82%). Most PPs reported that they suspect TB based on three cardinal symptoms: cough for >2 weeks (97%), fever (93%) and weight loss (82%). While 54% PPs considered the Xpert assay as the first test to diagnose MDR-TB, 32% were unaware of any test.Only 37% PPs were aware of whole genome sequencing for MDR diagnosis. A fifth of PPs selected Mantoux test use for the diagnosis of active TB. Less than a fourth of PPs knew about the second-line anti-TB drugs such as bedaquiline, delamanid or linezolid etc. and their availability either in the National TB Elimination Program (NTEP) or the private sector. Our study indicates considerable lack of awareness about pulmonary MDR-TB management among allopathic PPs in the study area and highlights the need for education and creating awareness about the same. It identified specific areas for developing an educational tool for PPs in India and elsewhere.
- 17 September 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (9) , e0004617
Open AccessAwareness of management of pulmonary multidrug-resistant tuberculosis (MDR-TB) among private practitioners in suburban areas of Pune city, India: Input for developing an educational tool
Private practitioners (PPs) play a major role in caring for people with tuberculosis (TB) in India. At the same time, PPs have limited access to continuing medical education and oversight especially with regards to recent changes in the management of multi-drug resistant (MDR- TB). As a part of a larger study aimed at developing an educational tool for improving multidrug-resistant TB management, we conducted a baseline knowledge assessment of MDR-TB among PPs in suburban areas of Pune City, India. This study with a cross-sectional design was conducted during July 2022 to May 2023 among 100 PPs, who either refer and/treat TB and MDR-TB cases in Pimpri-Chinchwad Municipal Corporation (PCMC) areas of Pune in Maharashtra State. The inquiry was made using an interview schedule focused on suspicion of pulmonary TB and MDR-TB, their diagnosis and treatment. The majority of PPs were allopathic practitioners (85%) practicing in private clinics (82%). Most PPs reported that they suspect TB based on three cardinal symptoms: cough for >2 weeks (97%), fever (93%) and weight loss (82%). While 54% PPs considered the Xpert assay as the first test to diagnose MDR-TB, 32% were unaware of any test.Only 37% PPs were aware of whole genome sequencing for MDR diagnosis. A fifth of PPs selected Mantoux test use for the diagnosis of active TB. Less than a fourth of PPs knew about the second-line anti-TB drugs such as bedaquiline, delamanid or linezolid etc. and their availability either in the National TB Elimination Program (NTEP) or the private sector. Our study indicates considerable lack of awareness about pulmonary MDR-TB management among allopathic PPs in the study area and highlights the need for education and creating awareness about the same. It identified specific areas for developing an educational tool for PPs in India and elsewhere.
- Open Access
- 27 November 2024
- Published by Wolters Kluwer Health in Medical Journal of Dr. D.Y. Patil Vidyapeeth
- Vol. 17 (Suppl 2) , S261-S262
COVID-19 Immunization for Adolescents: What does the Scientific Evidence Tell us?
- 27 November 2024
- Published by Wolters Kluwer Health in Medical Journal of Dr. D.Y. Patil Vidyapeeth
- Vol. 17 (Suppl 2) , S261-S262
Open AccessCOVID-19 Immunization for Adolescents: What does the Scientific Evidence Tell us?
- Open Access
- 17 September 2024
- Published by Medknow in Medical Journal of Dr. D.Y. Patil Vidyapeeth
- Vol. 17 (5) , 935-936
Anti-tuberculosis (TB) Drug Stockouts in India: Implementation Gaps, Implications for Patients and Public Health
- 17 September 2024
- Published by Medknow in Medical Journal of Dr. D.Y. Patil Vidyapeeth
- Vol. 17 (5) , 935-936
Open AccessAnti-tuberculosis (TB) Drug Stockouts in India: Implementation Gaps, Implications for Patients and Public Health
- Open Access
- 2 May 2024
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (5) , e0277023
Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases
Treatment decisions for tuberculosis (TB) in the absence of full drug-susceptibility data can result in amplifying resistance and may compromise treatment outcomes. Genomics of Mycobacterium tuberculosis ( M.tb ) from clinical samples enables detection of drug resistance to multiple drugs. We performed whole-genome sequencing (WGS) for 600 clinical samples from patients with tuberculosis to identify the drug-resistance profile and mutation spectrum. We documented the reasons reported by clinicians for referral. WGS identified a high proportion (51%) of pre-extensively drug-resistant (pre-XDR) cases followed by multidrug-resistant tuberculosis (MDR-TB) (15.5%). This correlates with the primary reason for referral, as non-response to the first-line treatment (67%) and treatment failure or rifampicin resistance (14%). Multivariate analysis indicated that all young age groups ( P < 0.05), male gender ( P < 0.05), and Beijing strain ( P < 0.01) were significant independent predictors of MDR-TB or MDR-TB+ [pre-extensively drug-resistant tuberculosis (XDR-TB) and XDR-TB]. Ser315Thr (72.5%) in the inhA gene and Ser450Leu in the rpoB gene (65.5%) were the most prevalent mutations, as were resistance-conferring mutations to pyrazinamide (41%) and streptomycin (61.33%). Mutations outside the rifampicin resistance-determining region (RRDR), Ile491Phe and Val170Phe, were seen in 1.3% of cases; disputed mutations in rpoB (Asp435Tyr, His445Asn, His445Leu, and Leu430Pro) were seen in 6% of cases, and mutations to newer drugs such as bedaquiline and linezolid in 1.0% and 7.5% of cases, respectively. This study on clinical samples highlights that there is a high proportion of pre-XDR cases and emerging resistance to newer drugs; ongoing transmission of these strains can cause serious threat to public health; and whole-genome sequencing can effectively identify and support precision medicine for TB. IMPORTANCE: The current study is based on real-world data on the TB drug-resistance profile by whole-genome sequencing of 600 clinical samples from patients with TB in India. This study indicates the clinicians’ reasons for sending samples for WGS, which is for difficult-to-treat cases and/or relapse and treatment failure. The study reports a significant proportion of cases with pre-XDR-TB strains that warrant policy makers’ attention. It reflects the current iterative nature of the diagnostic tests under programmatic conditions that leads to delays in appropriate diagnosis and empirical treatment. India had an estimated burden of 2.95 million TB cases in 2020 and 135,000 multidrug-resistant cases. However, WGS profiles of M.tb from India remains disproportionately poorly represented. This study adds a significant body of data on the mutation profiles seen in M.tb isolated from patients with TB in India, mutations outside the RRDR, disputed mutations, and resistance-conferring mutations to newer drugs such as bedaquiline and linezolid.
- 2 May 2024
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (5) , e0277023
Open AccessWhole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases
Treatment decisions for tuberculosis (TB) in the absence of full drug-susceptibility data can result in amplifying resistance and may compromise treatment outcomes. Genomics of Mycobacterium tuberculosis ( M.tb ) from clinical samples enables detection of drug resistance to multiple drugs. We performed whole-genome sequencing (WGS) for 600 clinical samples from patients with tuberculosis to identify the drug-resistance profile and mutation spectrum. We documented the reasons reported by clinicians for referral. WGS identified a high proportion (51%) of pre-extensively drug-resistant (pre-XDR) cases followed by multidrug-resistant tuberculosis (MDR-TB) (15.5%). This correlates with the primary reason for referral, as non-response to the first-line treatment (67%) and treatment failure or rifampicin resistance (14%). Multivariate analysis indicated that all young age groups ( P < 0.05), male gender ( P < 0.05), and Beijing strain ( P < 0.01) were significant independent predictors of MDR-TB or MDR-TB+ [pre-extensively drug-resistant tuberculosis (XDR-TB) and XDR-TB]. Ser315Thr (72.5%) in the inhA gene and Ser450Leu in the rpoB gene (65.5%) were the most prevalent mutations, as were resistance-conferring mutations to pyrazinamide (41%) and streptomycin (61.33%). Mutations outside the rifampicin resistance-determining region (RRDR), Ile491Phe and Val170Phe, were seen in 1.3% of cases; disputed mutations in rpoB (Asp435Tyr, His445Asn, His445Leu, and Leu430Pro) were seen in 6% of cases, and mutations to newer drugs such as bedaquiline and linezolid in 1.0% and 7.5% of cases, respectively. This study on clinical samples highlights that there is a high proportion of pre-XDR cases and emerging resistance to newer drugs; ongoing transmission of these strains can cause serious threat to public health; and whole-genome sequencing can effectively identify and support precision medicine for TB. IMPORTANCE: The current study is based on real-world data on the TB drug-resistance profile by whole-genome sequencing of 600 clinical samples from patients with TB in India. This study indicates the clinicians’ reasons for sending samples for WGS, which is for difficult-to-treat cases and/or relapse and treatment failure. The study reports a significant proportion of cases with pre-XDR-TB strains that warrant policy makers’ attention. It reflects the current iterative nature of the diagnostic tests under programmatic conditions that leads to delays in appropriate diagnosis and empirical treatment. India had an estimated burden of 2.95 million TB cases in 2020 and 135,000 multidrug-resistant cases. However, WGS profiles of M.tb from India remains disproportionately poorly represented. This study adds a significant body of data on the mutation profiles seen in M.tb isolated from patients with TB in India, mutations outside the RRDR, disputed mutations, and resistance-conferring mutations to newer drugs such as bedaquiline and linezolid.
- Open Access
- 28 December 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (12) , e0295508
Addressing patients’ unmet needs related to multidrug-resistant tuberculosis (MDR-TB) care: A qualitative research study from Pune city, India
We aimed to identify and describe the unmet needs of patients with multidrug-resistant tuberculosis (MDR-TB). As a part of larger cross-sectional mixed-methods (qualitative and quantitative data) study on pathways to MDR-TB care, here we present the qualitative component. We interviewed 128 (56 men and 72 women) individuals who had MDR-TB, aged > = 15 years, registered and treated under the National TB Elimination Program (NTEP) in Pune city of India. We carried out thematic analysis of participants’ narratives. We found that delays in diagnosis, lack of counseling, late referral to the NTEP and unwarranted expenditure were the main barriers to care that study participants experienced in the private sector. Provider dismissal of symptoms, non-courteous behavior, lack of hygiene in the referral centers, forced stay with other patients and lack of support for psychological/psychiatric problems were identified as a few additional challenges that participants faced at the NTEP care centers. Using qualitative data from experiences of participants with MDR-TB, we identify patients’ several unmet needs, attention to which can improve MDR-TB care. Educating private providers about MDR-TB risk and available rapid molecular assays can help the timely diagnosis of MDR-TB and reduce patients’ out of pocket costs. At the RNTCP/NTEP, measures such as training health workers to build rapport with patients, maintaining hygienic environments in the health centers with adequate isolation of participants with MDR from other serious cases, referral of patients with psychiatric symptoms to mental health specialists and monitoring drug shortages can help in improving care delivery.
- 28 December 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (12) , e0295508
Open AccessAddressing patients’ unmet needs related to multidrug-resistant tuberculosis (MDR-TB) care: A qualitative research study from Pune city, India
We aimed to identify and describe the unmet needs of patients with multidrug-resistant tuberculosis (MDR-TB). As a part of larger cross-sectional mixed-methods (qualitative and quantitative data) study on pathways to MDR-TB care, here we present the qualitative component. We interviewed 128 (56 men and 72 women) individuals who had MDR-TB, aged > = 15 years, registered and treated under the National TB Elimination Program (NTEP) in Pune city of India. We carried out thematic analysis of participants’ narratives. We found that delays in diagnosis, lack of counseling, late referral to the NTEP and unwarranted expenditure were the main barriers to care that study participants experienced in the private sector. Provider dismissal of symptoms, non-courteous behavior, lack of hygiene in the referral centers, forced stay with other patients and lack of support for psychological/psychiatric problems were identified as a few additional challenges that participants faced at the NTEP care centers. Using qualitative data from experiences of participants with MDR-TB, we identify patients’ several unmet needs, attention to which can improve MDR-TB care. Educating private providers about MDR-TB risk and available rapid molecular assays can help the timely diagnosis of MDR-TB and reduce patients’ out of pocket costs. At the RNTCP/NTEP, measures such as training health workers to build rapport with patients, maintaining hygienic environments in the health centers with adequate isolation of participants with MDR from other serious cases, referral of patients with psychiatric symptoms to mental health specialists and monitoring drug shortages can help in improving care delivery.
- Open Access
- 2 June 2023
- Published by Medknow in Medical Journal of Dr. D.Y. Patil Vidyapeeth
- Vol. 16 (Suppl 2) , S319-S320
TB Preventive Treatment (TPT) for Household Contacts in India: What has Changed?
- 2 June 2023
- Published by Medknow in Medical Journal of Dr. D.Y. Patil Vidyapeeth
- Vol. 16 (Suppl 2) , S319-S320
Open AccessTB Preventive Treatment (TPT) for Household Contacts in India: What has Changed?
- Open Access
- 16 November 2022
- Published by Elsevier in The Lancet Global Health
- Vol. 10 (12) , e1691-e1692
COVID-19 and global childhood tuberculosis notifications
- 16 November 2022
- Published by Elsevier in The Lancet Global Health
- Vol. 10 (12) , e1691-e1692
Open AccessCOVID-19 and global childhood tuberculosis notifications
- Open Access
- 1 November 2022
- Published by Medknow in Medical Journal of Dr. D.Y. Patil Vidyapeeth
- Vol. 15 (Suppl 2) , S140-S141
Dramatic Reduction in COVID-19 Testing
- 1 November 2022
- Published by Medknow in Medical Journal of Dr. D.Y. Patil Vidyapeeth
- Vol. 15 (Suppl 2) , S140-S141
Open AccessDramatic Reduction in COVID-19 Testing
- Open Access
- 5 August 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-16
Tuberculosis (TB) Aftermath: study protocol for a hybrid type I effectiveness-implementation non-inferiority randomized trial in India comparing two active case finding (ACF) strategies among individuals treated for TB and their household contacts
Background: Approximately 7% of all reported tuberculosis (TB) cases each year are recurrent, occurring among people who have had TB in the recent or distant past. TB recurrence is particularly common in India, which has the largest TB burden worldwide. Although patients recently treated for TB are at high risk of developing TB again, evidence around effective active case finding (ACF) strategies in this population is scarce. We will conduct a hybrid type I effectiveness-implementation non-inferiority randomized trial to compare the effectiveness, cost-effectiveness, and feasibility of two ACF strategies among individuals who have completed TB treatment and their household contacts (HHCs). Methods: We will enroll 1076 adults (≥ 18 years) who have completed TB treatment at a public TB unit (TU) in Pune, India, along with their HHCs (averaging two per patient, n = 2152). Participants will undergo symptom-based ACF by existing healthcare workers (HCWs) at 6-month intervals and will be randomized to either home-based ACF (HACF) or telephonic ACF (TACF). Symptomatic participants will undergo microbiologic testing through the program. Asymptomatic HHCs will be referred for TB preventive treatment (TPT) per national guidelines. The primary outcome is rate per 100 person-years of people diagnosed with new or recurrent TB by study arm, within 12 months following treatment completion. The secondary outcome is proportion of HHCs < 6 years, by study arm, initiated on TPT after ruling out TB disease. Study staff will collect socio-demographic and clinical data to identify risk factors for TB recurrence and will measure post-TB lung impairment. In both arms, an 18-month “mop-up” visit will be conducted to ascertain outcomes. We will use the RE-AIM framework to characterize implementation processes and explore acceptability through in-depth interviews with index patients, HHCs and HCWs (n = 100). Cost-effectiveness will be assessed by calculating the incremental cost per TB case detected within 12 months and projected for disability-adjusted life years averted based on modeled estimates of morbidity, mortality, and time with infectious TB. Discussion: This novel trial will guide India’s scale-up of post-treatment ACF and provide an evidence base for designing strategies to detect recurrent and new TB in other high burden settings. Trial registration: NCT04333485, registered April 3, 2020. CTRI/2020/05/025059 [Clinical Trials Registry of India], registered May 6 2020.
- 5 August 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-16
Open AccessTuberculosis (TB) Aftermath: study protocol for a hybrid type I effectiveness-implementation non-inferiority randomized trial in India comparing two active case finding (ACF) strategies among individuals treated for TB and their household contacts
Background: Approximately 7% of all reported tuberculosis (TB) cases each year are recurrent, occurring among people who have had TB in the recent or distant past. TB recurrence is particularly common in India, which has the largest TB burden worldwide. Although patients recently treated for TB are at high risk of developing TB again, evidence around effective active case finding (ACF) strategies in this population is scarce. We will conduct a hybrid type I effectiveness-implementation non-inferiority randomized trial to compare the effectiveness, cost-effectiveness, and feasibility of two ACF strategies among individuals who have completed TB treatment and their household contacts (HHCs). Methods: We will enroll 1076 adults (≥ 18 years) who have completed TB treatment at a public TB unit (TU) in Pune, India, along with their HHCs (averaging two per patient, n = 2152). Participants will undergo symptom-based ACF by existing healthcare workers (HCWs) at 6-month intervals and will be randomized to either home-based ACF (HACF) or telephonic ACF (TACF). Symptomatic participants will undergo microbiologic testing through the program. Asymptomatic HHCs will be referred for TB preventive treatment (TPT) per national guidelines. The primary outcome is rate per 100 person-years of people diagnosed with new or recurrent TB by study arm, within 12 months following treatment completion. The secondary outcome is proportion of HHCs < 6 years, by study arm, initiated on TPT after ruling out TB disease. Study staff will collect socio-demographic and clinical data to identify risk factors for TB recurrence and will measure post-TB lung impairment. In both arms, an 18-month “mop-up” visit will be conducted to ascertain outcomes. We will use the RE-AIM framework to characterize implementation processes and explore acceptability through in-depth interviews with index patients, HHCs and HCWs (n = 100). Cost-effectiveness will be assessed by calculating the incremental cost per TB case detected within 12 months and projected for disability-adjusted life years averted based on modeled estimates of morbidity, mortality, and time with infectious TB. Discussion: This novel trial will guide India’s scale-up of post-treatment ACF and provide an evidence base for designing strategies to detect recurrent and new TB in other high burden settings. Trial registration: NCT04333485, registered April 3, 2020. CTRI/2020/05/025059 [Clinical Trials Registry of India], registered May 6 2020.